Nanotherapeutics has assembled a world-class team to apply new biomanufacturing technologies with existing manufacturing capabilities for biologic products that will provide the DoD and the US Government with the ability to rapidly respond to emerging disease threats and chemical, biologic, radiological and nuclear (CBRN) events.
Additionally, Nanotherapeutics is able to leverage its facility and capabilities to provide manufacturing and process development services to the biopharmaceutical industry. Our primary manufacturing goal is to rapidly produce bulk drug substance according to the highest standards of quality. Along with its partners, Nanotherapeutics provides broad/flexible capabilities including:
- Development laboratories and pilot plant for performing optimization of upstream, downstream and formulation functions
- Biologics drug substance cGMP manufacturing space
- Analytical development
- Oversight of small molecule synthesis and product release
Nanotherapeutics' manufacturing capabilities include proteins, antibodies, viral, bacterial and recombinant protein vaccines and gene therapy vectors and drug products. We have an integrated team of partners to support product/process development and manufacturing, from the stage of clinical development through the manufacturing of commercial supply. Our highly experienced team provides expertise from preclinical development through final product licensure in all relevant biologics production platforms.